JP2011168588A5 - - Google Patents

Download PDF

Info

Publication number
JP2011168588A5
JP2011168588A5 JP2011026980A JP2011026980A JP2011168588A5 JP 2011168588 A5 JP2011168588 A5 JP 2011168588A5 JP 2011026980 A JP2011026980 A JP 2011026980A JP 2011026980 A JP2011026980 A JP 2011026980A JP 2011168588 A5 JP2011168588 A5 JP 2011168588A5
Authority
JP
Japan
Prior art keywords
gene
compound
apoptosis inducer
test compound
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011026980A
Other languages
English (en)
Japanese (ja)
Other versions
JP5213972B2 (ja
JP2011168588A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2011026980A priority Critical patent/JP5213972B2/ja
Priority claimed from JP2011026980A external-priority patent/JP5213972B2/ja
Publication of JP2011168588A publication Critical patent/JP2011168588A/ja
Publication of JP2011168588A5 publication Critical patent/JP2011168588A5/ja
Application granted granted Critical
Publication of JP5213972B2 publication Critical patent/JP5213972B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011026980A 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 Expired - Fee Related JP5213972B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011026980A JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004115404 2004-04-09
JP2004115404 2004-04-09
JP2011026980A JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006512126A Division JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012046652A Division JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Publications (3)

Publication Number Publication Date
JP2011168588A JP2011168588A (ja) 2011-09-01
JP2011168588A5 true JP2011168588A5 (https=) 2012-04-19
JP5213972B2 JP5213972B2 (ja) 2013-06-19

Family

ID=35124844

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006512126A Expired - Fee Related JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2011026980A Expired - Fee Related JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2012046652A Expired - Fee Related JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006512126A Expired - Fee Related JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012046652A Expired - Fee Related JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Country Status (5)

Country Link
US (3) US8193332B2 (https=)
EP (4) EP2520652B1 (https=)
JP (3) JP4761389B2 (https=)
KR (1) KR101234281B1 (https=)
WO (1) WO2005097189A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4299299B2 (ja) * 2003-05-19 2009-07-22 株式会社ジーンケア研究所 癌細胞に対するアポトーシス誘導剤
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
KR101330229B1 (ko) * 2004-11-19 2013-11-15 가부시키가이샤 진케어켄큐쇼 암세포 특이적 세포증식 억제제
EP1846550A2 (en) * 2005-02-10 2007-10-24 Centre National De La Recherche Scientifique (Cnrs) Use of the mcm8 gene for the preparation of a pharmaceutical composition
EP1915622A2 (en) * 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
WO2008047574A1 (fr) * 2006-09-28 2008-04-24 Genecare Research Institute Co., Ltd. Sensibilisateur pour agent anticancéreux
JP4940412B2 (ja) * 2006-10-16 2012-05-30 財団法人ヒューマンサイエンス振興財団 抗癌性物質のスクリーニング方法
CA2666584A1 (en) * 2006-10-17 2008-04-24 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010034487A2 (en) * 2008-09-23 2010-04-01 Silence Therapeutics Ag Means for inhibiting the expression of orc-1
WO2010045526A1 (en) * 2008-10-17 2010-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Geminin inhibitors as tumor treatment
US20110237649A1 (en) * 2008-12-04 2011-09-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
WO2010102058A2 (en) * 2009-03-04 2010-09-10 Curna, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
ES2854004T3 (es) * 2009-07-24 2021-09-20 Curna Inc Tratamiento de enfermedades relacionadas con Sirtuina 6 (SIRT6) mediante inhibición del transcrito antisentido natural para SIRT6
SG183304A1 (en) 2010-02-17 2012-09-27 Takeda Pharmaceutical Heterocyclic compound
WO2011150418A2 (en) * 2010-05-28 2011-12-01 Case Western Reserve University Compositions and methods for treating pathologies
WO2012090479A1 (en) * 2010-12-28 2012-07-05 Oncotherapy Science, Inc. Mcm7 as a target gene for cancer therapy and diagnosis
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR101623814B1 (ko) 2014-02-21 2016-05-24 두산중공업 주식회사 수냉각 발전기의 분리형 냉각수 순환 구조 및 그에 따른 냉각 방법
JP2015167527A (ja) * 2014-03-07 2015-09-28 学校法人東京理科大学 標的タンパク質の量の低減のためのポリペプチド、単離された核酸、組み換えベクター、及び形質転換体
WO2016102517A1 (en) * 2014-12-23 2016-06-30 Centre National De La Recherche Scientifique Use of rad18 inhibitors in the treatment of tumors
CN104673801B (zh) * 2015-02-12 2018-09-11 中山大学附属第三医院 一种肝癌基因ndc80及其应用
JP6854246B2 (ja) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド 尿サンプルの分析方法
EP3304084B1 (en) 2015-06-08 2022-03-23 Arquer Diagnostics Limited Methods and kits
WO2018053035A1 (en) * 2016-09-13 2018-03-22 The Jackson Laboratory Targeted dna demethylation and methylation
WO2018079287A1 (ja) * 2016-10-26 2018-05-03 デンカ株式会社 変異型ヒトＤＮＡポリメラーゼε
WO2019005754A1 (en) * 2017-06-26 2019-01-03 The Cleveland Clinic Foundation TREATMENT AGAINST CANCER
EP3851528A4 (en) * 2018-09-12 2023-12-06 Institute for Basic Science COMPOSITION FOR INDUCATING DEATH OF CELLS HAVING MUTATED GENE AND METHOD FOR INDUCATING DEATH OF CELLS HAVING MODIFIED GENE USING THE COMPOSITION
JP2022020872A (ja) * 2020-06-01 2022-02-02 均 石井 抗がん剤。

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923738A1 (en) * 1996-06-11 1999-06-23 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
GB0004193D0 (en) * 2000-02-22 2000-04-12 Isis Innovation A genetic determinant for malignant melanoma
US6773883B2 (en) * 2000-07-31 2004-08-10 The Brigham & Women's Hospital, Inc. Prognostic classification of endometrial cancer
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
WO2002102981A2 (en) * 2001-06-15 2002-12-27 The Trustees Of Columbia University In The City Of New York SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
AU2002362030A1 (en) * 2001-11-27 2003-06-10 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
AU2003250831A1 (en) * 2002-06-12 2003-12-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
WO2004033666A2 (en) * 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
JP2006523456A (ja) * 2003-04-15 2006-10-19 アバロン ファーマシューティカルズ，インコーポレイテッド 分子細胞遺伝学的方法を用いる癌連鎖遺伝子および治療標的の確認
WO2004094636A1 (en) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
JP4299299B2 (ja) 2003-05-19 2009-07-22 株式会社ジーンケア研究所 癌細胞に対するアポトーシス誘導剤
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
KR101330229B1 (ko) 2004-11-19 2013-11-15 가부시키가이샤 진케어켄큐쇼 암세포 특이적 세포증식 억제제

Similar Documents

Publication Publication Date Title
JP2011168588A5 (https=)
Zhang et al. Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR‐138 targets TERT and PD‐L1
JP2011037847A5 (https=)
Yu et al. Downregulation of miR‐29 contributes to cisplatin resistance of ovarian cancer cells
Neudecker et al. Emerging roles for microRNAs in perioperative medicine
Alegre et al. Circulating biomarkers in malignant melanoma
Skommer et al. Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death
Wang et al. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis
Nidadavolu et al. Identification of microRNAs dysregulated in cellular senescence driven by endogenous genotoxic stress
Xue et al. MicroRNA-targeted therapeutics for lung cancer treatment
Johnson et al. Neurodegeneration as an RNA disorder
Wang et al. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9
JP2011162558A5 (https=)
HK1200837A1 (en) Compositions and methods for silencing aldehyde dehydrogenase
JP2012050449A5 (https=)
Yang et al. miR‑155 functions downstream of angiotensin II receptor subtype 1 and calcineurin to regulate cardiac hypertrophy
NZ617003A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NO20092965L (no) Sammensetninger og fremgangsmater for a forhindre kreft med cupredoksiner
WO2014162008A3 (en) Biomarker signatures for predicting drug response in hodkin's lymphoma
JP2014221834A5 (https=)
Ding et al. HCV infection induces the upregulation of miR-221 in NF-κB dependent manner
Huang et al. Circular RNAs in renal cell carcinoma: from mechanistic to clinical perspective
JP2016528914A5 (https=)
JP2016506412A5 (https=)
Xie et al. Circular RNA: a new expectation for cardiovascular diseases